Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
Linda DiMeglio, MD
Primary Investigator
Brief description of study
The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: type 1 diabetes mellitus, Riley
-
Age: Between 4 Years - 12 Years
-
Gender: All
Inclusion Criteria
Diagnosed with Type 1 diabetes for at least 1 year
Currently on multiple daily injections
No history of asthma
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
